Telomir Pharmaceuticals develops a novel treatment that binds critical metals to interrupt enzyme function.
Telomir Pharmaceuticals has raised $1.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2026.
Telomir Pharmaceuticals's investors include Starwood Property Trust, Bayshore Capital.
Telomir Pharmaceuticals is headquartered in Baltimore, United States.
Telomir Pharmaceuticals develops a novel treatment that binds critical metals to interrupt enzyme function.
Telomir Pharmaceuticals is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Telomir Pharmaceuticals — Funding & Investors." VCBacked, April 24, 2026, https://www.vcbacked.co/company/telomir-pharmaceuticals. Accessed October 6, 2026.
VCBacked. (2026). Telomir Pharmaceuticals — Funding & Investors. Retrieved October 6, 2026, from https://www.vcbacked.co/company/telomir-pharmaceuticals
{{cite web |title=Telomir Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/telomir-pharmaceuticals |website=VCBacked |access-date=October 6, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated